Polyherbal Capsule Formulation for Joint Health

NCT ID: NCT02157701

Last Updated: 2015-10-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 108 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2015-04-30

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled, study in subjects with exercise-related knee pain/discomfort to determine the efficacy of a polyherbal capsule compared to placebo capsule in improving exercise capacity and overall parameters of joint health.

Detailed Description

Subjects will come to the study site at Visit 1 for screening assessments (which will occur within 14 days before the start of the run-in period) and to answer questions associated with habitual diet, exercise capacity, and level of activity. Those subjects who meet initial inclusion/exclusion criteria will undergo a run-in period of at least 7 days at home to discontinue use of all concurrent dietary supplements. Subjects will then return to the study site at Visit 2 (Baseline; Day 0) for further assessments and those meeting all inclusion/exclusion criteria will be enrolled into the study and randomly assigned to study product.

Approximately 108 subjects (54 per treatment group) will be enrolled in the study. Subjects will be evaluated at Visit 3 (Day 14), Visit 4 (Day 45), Visit 5 (Day 60, phone call), and Visit 6 (Day 90). Exercise capacity (ie, 6-minute timed walk distance test) will be assessed, along with overall knee wellness and joint-related symptoms using WOMAC, PGA, Knee Pain Rating Scale, and rescue medication usage. Safety will be assessed by collecting adverse events (AEs) and clinical laboratory data.

Conditions

Knee Discomfort; Pain Physical Activity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Polyherbal capsule

1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.

Group Type: EXPERIMENTAL

Polyherbal capsule

Intervention Type: DIETARY_SUPPLEMENT

Placebo capsule

1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.

Group Type: PLACEBO_COMPARATOR

Placebo capsule

Intervention Type: DIETARY_SUPPLEMENT

Interventions

Polyherbal capsule

Intervention Type: DIETARY_SUPPLEMENT

Placebo capsule

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• ≥ 25 and ≤ 75 years of age with history of joint discomfort in at least 1 knee following daily activities but otherwise healthy
• body mass index (BMI) ≥ 25 and ≤ 40 kg/m2
• sum of ≥ 60 mm (based on 100-mm visual analog scale [VAS]) on the first 2 questions (ie, "How much pain have you had when walking on a flat surface?" "How much pain have you had when going up or down stairs?") of the WOMAC (Section A; Appendix 2)
• females of child bearing potential must agree to use appropriate birth control methods during the entire study period
• agree not to initiate any new exercise or diet programs during the entire study period
• agree not to change their current diet or exercise program, or to use other dietary supplements other than the test product, during the entire study period
• understand the study procedures and sign the forms providing informed consent to participate in the study, and authorize the release of relevant protected health information of the study investigator.

Exclusion Criteria

• use of NSAIDS during the study (however 81 mg of aspirin daily for cardioprotection is allowed)
• daily use of dietary supplements and herbal supplements beginning at the screening visit and during the study
• subjects with any history of chronic inflammatory disease, immune system disorder or auto-immune disorder including but not limited to the following: AIDS/HIV, ankylosing spondylitis, dermatomyositis, fibromyalgia, Grave's disease, Hashimoto's thyroiditis, lupus, multiple sclerosis, myasthenia gravis, pernicious anemia, systemic vasculitis conditions such as temporal arteritis, primary biliary cirrhosis, psoriasis, Raynaud's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma including the CREST syndrome subset, Sjogren's syndrome, temporal arteritis, inflammatory bowel disease, vitiligo, or chronic infections such as Lyme disease, tuberculosis, endocarditis, and osteomyelitis;
• history of or current diagnosis of gout or pseudogout
• use of any immunosuppressive drugs or biologic products in the last 12 months (including steroids [except for inhaled and topical dose forms])
• antibiotic use, anticoagulants, intra-articular steroids in past 3 months
• intra-articular hyaluronic acid in past 6 months
• subjects with chronic pain syndrome and who are in the judgment of the Investigator unlikely to respond to any therapy (Note that chronic depression and chronic anxiety are known magnifiers of chronic pain syndrome and are also exclusionary. Chronic fatigue syndrome overlaps with the chronic pain domain and is also exclusionary. In addition, fibromyalgia is a central nervous system (CNS) disorder and overlaps with the chronic pain and chronic fatigue domains and is exclusionary as well.)
• any significant GI condition that would potentially interfere with the evaluation of the study product including but not limited to inflammatory bowel disease (ulcerative colitis or Crohn's), history of lap band surgery, history of perforation of the stomach or intestines, or gastroparesis
• clinically significant renal, hepatic, GI, endocrine (including diabetes mellitus), neurologic (particularly balance or neuropathy problems), or hematologic disorders; or chronic obstructive pulmonary disease (COPD), asthma, lung disease, or heart disease that limits exercise capacity (such as peripheral artery disease, ischemic heart disease, heart failure, stroke in the last year, or uncontrolled hypertension [systolic blood pressure over 140 mmHg and/or diastolic above 90 mmHg]) or causes abnormal respiratory or cardiovascular responses during the 6-minute timed walk distance test (such as angina or arrhythmias)
• known allergy or sensitivity to herbal ingredients in the test products, acetaminophen, olive oil, or soy
• history or presence of cancer in the last 5 years (except basal cell carcinoma of skin or in-situ cervical cancer)
• recent history of (within 2 years) alcohol or substance abuse
• participation in a clinical study with exposure to any non-registered drug product within 30 days prior to this study
• individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk, including subjects who are bed or wheelchair-bound or those who have any physical disability which could interfere with their ability to walk or perform the exercise capacity assessments included in this protocol (eg, history of knee or hip joint replacement surgery)
• diabetes not controlled by medication
• untreated or unstable thyroid dysfunction (hyper- or hypo-thyroidism)
• subjects with a significant mental health disorder (bipolar disorder, chronic depression requiring medication, chronic anxiety disorder, obsessive compulsive disorder, or active eating disorders including anorexia nervosa or bulimia)
• subjects with a history of seizures in the last 5 years or dizziness when exercising
• knee arthroscopy in the previous year or surgeries of the lumbar spine, hip, knee, ankle or foot
• surgery scheduled prior to study completion
• pregnant or lactating women
• walk > 575 meters (1886 feet), or have a Knee Pain Rating Scale (Appendix 4) score of < 40 mm on a 100 mm VAS that assesses knee discomfort, after the 6-minute timed walk distance test.

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Procter and Gamble

INDUSTRY

Sponsor Role: collaborator

NewChapter, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jose Brum, MD

Role: STUDY_DIRECTOR

Procter and Gamble

Locations

Akta Medika Medical Group Research Division

Homestead, Florida, United States

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Radiant Research

Dallas, Texas, United States

Benchmark Research

San Angelo, Texas, United States

Radiant Research

San Antonio, Texas, United States

Countries

United States

Other Identifiers

2014020

Identifier Type: OTHER

Identifier Source: secondary_id

NEWC2600

Identifier Type: -

Identifier Source: org_study_id